Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Clinical Trial ID NCT00258700

PubWeight™ 1.79‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00258700

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv Prev Med 2011 0.88
2 A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child 2008 0.88
Next 100